An interventional study of Non-ECG-gated computed tomography in Chest Pain and Acute Coronary Syndromes (ACS), sponsored by Universitair Ziekenhuis Brussel. Recruiting at 1 site in Belgium. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Chest pain represents a common reason for consultation to emergency room. This symptom can be explained by a broad spectrum of conditions, from benign musculoskeletal or esophageal pain to life-threatening disease such as aortic dissection, pulmonary embolism, and myocardial infarction.
There are already different diagnostic tools to quickly identify most dangerous diseases, for example electrocardiogram, blood samples with specific markers of cardiac injury, chest X-ray and echography. In case a doubt of disease is raised after the first clinical evaluation, it is possible to proceed with more complex, expensive and invasive examinations, namely a computed tomography (CT) scan or an invasive coronary angiography (ICA).
CT scan allows the diagnosis of various conditions such as pleural, pulmonary, pericardial and vascular disease such as pneumonia, pneumothorax, pleural and pericardial fluid, pulmonary embolism (PE), acute aortic dissection (AOD). In order to see the pulmonary, aortic and coronary arteries, a contrast injection is needed. Moreover, since the heart and the aortic root are continuously moving, specific technical measures to obtain good quality images are needed.
Recently, a new CT scan system has been developed. It allows to obtain good quality images of the heart and aortic root using an estimated heart rhythm, without ECG-gating. This allows to perform a CT scan of the heart in a reduced amount of time, and without need for controlling heart rate. Moreover, it is possible to obtain information on both aortic, coronary, and pulmonary artery with the same contrast injection. This may be of great interest in the context of patients presenting at the emergency room with chest pain and with a suspicion of pulmonary embolism, myocardial infarction, or aortic dissection, since with a single fast exam it is possible to rule out all these conditions.
Coronary arteries are very small vessels, and the accuracy of this new technique in identifying a significant obstruction is still to be proved. At present, patients with chest pain and a suspicion of myocardial infarction undergo an invasive coronary angiography. If this new tool proves to be reliable, it will be possible to reduce the number of useless invasive examination in patients in which the presence of coronary artery disease (CAD) is ruled-out. In addition, the CT scan can help quickly and effectively plan treatment when worrying abnormalities are detected in the coronary arteries that are associated with a higher risk.
Therefore, this clinical trial (further on referred to as "trial") will evaluate the investigational medicinal product (IMP), ECG-less Revolution Apex Elite system (GE Healthcare, Waukesha, WI -USA) for the diagnosis of coronary artery disease. The purpose of this trial is to learn about: the accuracy of this new CT system compared to the gold standard invasive coronary angiography in diagnosing coronary artery disease. The number of patients receiving an alternative diagnosis such as pulmonary embolism, aortic dissection, pulmonary, pleural or pericardial disease will be evaluated. Finally, the prognostic predictive value of the CT compared with ICA, in predicting myocardial infarction, coronary revascularization, and cardiac death at a follow-up of 18 months will be assessed. Patient will undergo a computer tomography examination with this new technique, evaluating both pulmonary, aortic, and coronary arteries. Then, as indicated by current guidelines, they will undergo an invasive coronary angiography.
Study Rationale The aim is to investigate the potential role of CCTA in patients presenting to the emergency room with thoracic pain and elevated troponins. Using a single contrast bolus and a lower radiation dose, the new ECG-less CCTA could help exclude life-threatening conditions such as PE and AAD, while providing valuable information about the coronary arteries. Patients with normal coronary arteries could be safely discharged without invasive examinations, thus avoiding pro-cedural risks and optimizing both time and resources for medical institutions. However, since the diagnostic role of ECG-less CCTA in ACS has not yet been demonstrated, current guidelines and best practices will be followed in the management of enrolled patients. Decisions regard-ing PCI will be based on coronary angiography, coronary physiology, and intravascular imaging, as currently recommended by international guidelines.
The negative and positive predictive value of the ECG-less CCTA compared to the standard of care (ICA) in patients clinically considered at risk for NSTEMI will be assessed. Additionally, the prognostic predictive value of CCTA in this clinical context, in compari-son to ICA will be evaluated. If the prognostic value of CCTA is similar to that of ICA, it will be possible to reduce the use of invasive procedures in favor of non-invasive exams, thereby saving time, contrast, and radia-tion dose for the patient.
Primary Objectives
Secondary Objectives
ECG-less CT Patients will undergo scanning with a Revolution Apex Elite system (GE Healthcare, WI, USA), using hyperdrive pulmonary CT angiography (523mm/s with 0.28s/rotation gantry speed). Images will be acquired using the ECG-less Cardiac software (GE Healthcare, WI, USA), without the need for patient-attached ECG leads. The system uses a wide detector coverage of 160mm to provide full heart coverage and a fast gantry speed of 0.23 seconds per rotation to perform imaging in a single cardiac cycle. An estimation of the heart rhythm must be provided, which is always available since emergency patients are already monitored with finger pulse oximeter. Based on the heart rhythm the scanner simulates an ECG signal. This simulated ECG signal provides virtual gating of the scan. Acquisition can be performed over one full heart cycle, three-quarters, or half cycle, depending on heart rate. Advanced software tools including SmartPhase (automated phase selection) and SnapShot Freeze 2 (optimized volume registration) will be used to enhance image quality and correct for motion. After a short delay of 5-12 sec, allowing contrast to pass from the pulmonary circulation into the aorta and coronary arteries, a coronary CT angiography will be performed using the same contrast bolus. No additional contrast will be administered for cardiac imaging. No intravenous β-blocker or sublingual nitroglycerin will be administered. The total added exam time (including heart rhythm assessment, scan preparation, delay, and the acquisition itself) is estimated at 1-2 minutes.
Invasive coronary angiography and revascularization Patients will undergo an ICA following local and international best practices. The UZ Brussel in-terventional department is a high-volume center with experience in complex percutaneous coronary interventions (PCI). The procedures will be performed with trans-radial access when feasible. Any attention will be paid to reduce the total amount of contrast.
In case of moderate stenosis, the operator will use the invasive FFR to indicate PCI. The use of intravascular imaging is encouraged.
In case of significant CAD, patients will be treated with PCI following the ESC guidelines. The choice of interventional technique and DAPT regimen is left to the operator and the treating cardiologist.
Complete revascularization will be pursued either during the same hospitalization or within one month.
389 studies on the registry are indexed under Chest Pain; 65 are open to participants now.
This study's planned enrollment of 230 is above the median of 128 across 205 interventional studies indexed under Chest Pain.
Browse Chest Pain studies →Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Admission at the ER with acute chest pain and at least one of the follow-ing:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be before scanned with a ECG-less CCTA and then undergo invasive coronary angiography. There is one single arm.
Radiation: Non-ECG-gated computed tomography
Scanning with a Revolution Apex Elite system (GE Healthcare, WI, USA), using hyperdrive pulmonary CT angiography (523mm/s with 0.28s/rotation gantry speed). Images will be acquired using the ECG-less Cardiac software (GE Healthcare, WI, USA), without the need for patient-attached ECG leads. The system uses a wide detector coverage of 160mm to provide full heart coverage and a fast gantry speed of 0.23 seconds per rotation to perform imaging in a single cardiac cycle. An estimation of the heart rhythm must be provided, based on the heart rhythm the scanner simulates an ECG signal. This simulated ECG signal provides virtual gating of the scan. Advanced software tools including SmartPhase (automated phase selection) and SnapShot Freeze 2 (optimized volume registration) will be used. After a short delay of 5-12 sec, allowing contrast to pass from the pulmonary circulation into the aorta and coronary arteries, a coronary CT angiography will be performed using the same contrast bolus.
Diagnostic accuracy of ECG-less CCTA for detecting obstructive coronary artery disease (defined as luminal narrowing ≥ 50%), compared to invasive coronary angiography
In both studies, sensitivity, specificity, positive and negative predictive value will be calculated. Diagnostic accuracy will be assessed using the McNemar test to compare CCTA with ICA. Cohen's Kappa agreement test will be used to evaluate agreement in diagnostic categorization between the two modalities.
Time frame: Up to 12 weeks
Accuracy of CCTA in detecting high-risk CAD such as LM, proximal LAD and multivessel disease compared to invasive coronary angigoraphy
Accuracy of CCTA in detecting high-risk CAD such as LM, proximal LAD and multivessel disease compared to invasive coronary angigoraphy
Time frame: Up to 12 weeks
Possibility of CT-derived FFR in ECG-less CCTA
We will explore the feasibility of performing fractional flow reserve (FFR)-CT analysis on ECG-less CCTA images. The added diagnostic value of FFR-CT will be evaluated comparing diagnostic accuracy of CCTA with and without FFR, using ICA as the reference.
Time frame: Up to 12 weeks
Other conditions rather than CAD
The diagnosis of conditions other than CAD such as aortic dissection, pulmonary embolism, pneumonia, pleural fluid, pneumothorax, and pericardial fluid will be recorded
Time frame: Up to 12 weeks
Outcome prediction of ECG-less CCTA compared to ICA
A follow-up at 18 months will assess the occurrence of adverse events (ischemia-driven revascularization, myocardial infarction, and cardiac death). The groups of patients with positive and negative CT scan and ICA will be compared using Chi-squared test or Fisher's exact test as appropriate. For the analysis of binary outcomes, logistic regression will be utilized to establish the binary classifier for ROC curve analysis. Kaplan-Meier curves will be used to describe the event-free survival; differences between groups will be tested with the Log-Rank test. Renal function will be monitored by assessing eGFR at the time of hospitalization, before discharge, and at 18 months.
Time frame: at 18 months follow up
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 85 non-industry interventional studies with no phase under Chest Pain, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 24 months is close to that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitair Ziekenhuis Brussel →